Finoriq research workspace
AVANOS MEDICAL, INC. (AVNS) Company Overview
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America. Review AVNS filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
- Company
- AVANOS MEDICAL, INC. (AVNS)
- Ticker
- AVNS
- Market Cap
- $1.2B
- Latest Price
- $24.98
- Industry
- Industrial Specialties
AVANOS MEDICAL, INC. (AVNS) Current Valuation Metrics
Static valuation preview for AVANOS MEDICAL, INC. (AVNS). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 1.63x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 31.8x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -6.4% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 3.1% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.49x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.